SCHEMBL1160941

SCHEMBL1160941

O=c1c(O)c(-c2ccc3c(c2)OC(c2ccccc2)(c2ccccc2)O3)oc2cc(O)cc(O)c12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.65
KMT2A Q03164 9/20 0.65
CYP1A2 P05177 8/20 0.65
ABCB1 P08183 8/20 0.65
CYP1A1 P04798 7/20 0.65
CYP1B1 Q16678 7/20 0.65
CYP3A4 P08684 6/20 0.65
CYP2C9 P11712 6/20 0.65
XDH P47989 6/20 0.65
FTO Q9C0B1 6/20 0.65
MAPT P10636 5/20 0.65
BCHE P06276 4/20 0.65
CYP2D6 P10635 4/20 0.65
ACHE P22303 4/20 0.65
CYP2C19 P33261 4/20 0.65
CA12 O43570 4/20 0.65
PPARG P37231 4/20 0.65
CA7 P43166 4/20 0.65
TRPC5 Q9UL62 4/20 0.65
MAOA P21397 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17620177 0.87 ABCB1 (0.68) MEN1KMT2ACYP1A2ABCB1CYP1A1
SCHEMBL22710103 0.84 POLH (0.52) MEN1KMT2ACYP1A2ABCB1CYP1A1
SCHEMBL17620272 0.84 POLH (0.66) MEN1KMT2ACYP1A2ABCB1CYP1A1
SCHEMBL14254528 0.84 MEN1 (0.65) MEN1KMT2ACYP1A2ABCB1CYP1A1
SCHEMBL17620220 0.83 POLH (0.60) MEN1KMT2ACYP1A2ABCB1CYP1A1
SCHEMBL17620269 0.82 POLH (0.52) MEN1KMT2ACYP1A2ABCB1CYP1A1
Galangin SCHEMBL29393121 0.80 MEN1 (1.00) MEN1KMT2ACYP1A2ABCB1CYP1A1
Galangin SCHEMBL117225 0.80 MEN1 (1.00) MEN1KMT2ACYP1A2ABCB1CYP1A1
Quercetin SCHEMBL4173190 0.78 MEN1 (0.87) MEN1KMT2ACYP1A2ABCB1CYP1A1
Quercetin SCHEMBL3958393 0.78 MEN1 (0.87) MEN1KMT2ACYP1A2ABCB1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021104416-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (CN) 2021-06-03 WO disclosed
US-20210139447-A1 Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2021-05-13 US disclosed
EP-2627691-B1 DEGRADABLE POLYCARBONATES TEXAS A&M UNIV (US) 2020-11-25 EP disclosed
WO-2020012003-A1 LIPOPHENOLIC FLAVONOID DERIVATIVES USEFUL TO REDUCE CARBONYL AND OXIDATIVE STRESSES (COS) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2020-01-16 WO disclosed
EP-2460810-B1 NOVEL FLAVANONE DERIVATIVE UNIV OKAYAMA NAT UNIV CORP (JP) 2015-07-15 EP disclosed
US-8916526-B2 Flavanone derivative NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) 2014-12-23 US disclosed
US-20120202980-A1 Novel Flavanone Derivative NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) 2012-08-09 US disclosed
EP-2468741-A1 Novel quercetin derivatives, their preparation, pharmaceutical compositions containing them and their use Bel/Novamann International s.r.o. (SK) 2012-06-27 EP disclosed
EP-2460810-A1 NOVEL FLAVANONE DERIVATIVE National University Corporation Okayama University (JP) 2012-06-06 EP disclosed
WO-2011013735-A1 NOVEL FLAVANONE DERIVATIVE 国立大学法人 岡山大学 (JP) 2011-02-03 WO disclosed
US-20090182133-A1 BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL AGENTS SINGAPORE POLYTECHNIC 2009-07-16 US disclosed
US-20090182133-A1 BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL AGENTS SINGAPORE POLYTECHNIC 2009-07-16 US disclosed
US-20090182133-A1 BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL AGENTS SINGAPORE POLYTECHNIC 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182133-A1 BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL AGENTS SARS1, MAVS, ACE2 MEN1 4730/4885KMT2A 3631/4885CYP1A2 819/4885
US-20120202980-A1 Novel Flavanone Derivative GALE, VRK1, GALK1 MEN1 4827/4885KMT2A 2320/4885CYP1A2 596/4885
US-20210139447-A1 Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS) LPO, NQO1, CAT MEN1 3920/4885KMT2A 4226/4885CYP1A2 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.